Trial reportFrontiers in oncology2026
Multicenter clinical application of regulatory dual-channel digestive tract reconstruction with pylorus-preserving approach in advanced gastric cancer.
Trial report in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the clinical significance of regulatory dual-channel digestive tract reconstruction with a pylorus-preserving approach in advanced gastric cancer through a multicenter study. Methods: A total of 137 gastric cancer patients who underwent radical gastrectomy at three hospitals in Mianyang, China, between March 2018 and March 2023 were included. Patients were divided into a study group (n=68) undergoing regulatory dual-channel reconstruction with pylorus preservation and a control group (n=69) receiving total gastrectomy with Roux-en-Y reconstruction. Operative time, intraoperative blood loss, postoperative complications, and quality of life were compared. Results: No significant differences were found between the groups regarding demographic and clinical characteristics, operative time, intraoperative blood loss, gastrointestinal function recovery, or hospital stay (P>0.05). Postoperative complications, including pulmonary infections, anastomotic leakage, gastrointestinal bleeding, and reflux esophagitis, also showed no significant differences (P>0.05). However, dumping syndrome was significantly less frequent in the study group (P<0.05). Both groups showed improvement in functional status and overall health from 1 to 24 months postoperatively. The study group had significantly higher physical function scores at 24 months (P<0.05), along with better emotional function and overall health scores from 6 to 24 months (P<0.05). Additionally, diarrhea scores were significantly lower in the study group at 1 and 6 months (P<0.05), while other functional and symptom domains showed no differences (P>0.05). Conclusion: Regulatory dual-channel digestive tract reconstruction with pylorus preservation is a safe and effective approach that improves postoperative quality of life in patients with advanced gastric cancer. Synopsis: Pylorus-preserving dual-channel reconstruction in advanced gastric cancer improves quality of life, reduces dumping syndrome, and shows comparable safety to total gastrectomy with Roux-en-Y.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.